Dr. Patnaik on a Study Examining SL-401 in Patients With Myeloproliferative Neoplasms

Mrinal S. Patnaik, MBBS
Published: Sunday, Dec 04, 2016

Mrinal S. Patnaik, MBBS, hematologist, Mayo Clinic, discusses a study investigating SL-401 in patients with myeloproliferative neoplasms during the American Society of Hematology (ASH) Annual Meeting.
SL-401 is a monoclonal antibody conjugate which targets a protein called CD-123, Patnaik explains. CD-123 is conjugated with a diphtheria toxin which increases its efficacy in killing malignant cells, Patnaik said.

The study was designed based on the success seen with CD-123 in a rate, but agressive, blood cancer called blastic plasmacytoid dendritic cell neoplasm (BPDCN).

<<< View more from the 2016 ASH Annual Meeting

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: The Next Generation in Renal Cell Carcinoma Treatment: An Oncology Nursing Essentials WorkshopJul 31, 20181.5
Publication Bottom Border
Border Publication